Moderna Surprises Markets by Returning to Profitability
Cambridge, Friday, 6 November 2026.
Defying Wall Street forecasts of steep losses, Moderna reported a $200 million third-quarter profit and raised its 2026 revenue growth projection to as high as 25%.
Moderna’s Q3 2026 Turnaround: Profitability Returns After Losses
Moderna (NASDAQ: MRNA) delivered a financial rebound in the third quarter of 2026, reporting GAAP net income of $200 million ($0.2 billion) and GAAP diluted earnings per share (EPS) of $0.38, marking a dramatic shift from a $200 million net loss in the same period of 2025. The company’s total revenue reached $1.3 billion, representing a 29% increase year-over-year from $1.016 billion in Q3 2025. This performance significantly exceeded market expectations, with revenue surpassing the consensus estimate of $890.25 million by $422.75 million and EPS beating the anticipated loss of $1.10 by $1.48. These figures were released in a November 6, 2026 press release and confirmed by subsequent financial reports [1][3].
Revised Guidance Signals Confidence in Growth Trajectory
In response to its stronger-than-expected Q3 performance, Moderna revised its full-year 2026 revenue growth guidance to a range of 15% to 25%, a substantial upgrade from its prior forecast of up to 10% growth. This revision reflects the company’s operational momentum, including the U.S. FDA approval of mFLUSIVA—Moderna’s fifth globally approved commercial product—and positive Phase 3 clinical data for intismeran in melanoma treatment [1]. Management also adjusted its 2026 operating expense outlook downward by approximately $200 million and increased its projected year-end cash balance to between $8.1 billion and $8.3 billion, reinforcing financial stability [1].
Revenue Breakdown and Market Response
Moderna’s Q3 2026 revenue of $1.3 billion was geographically distributed with $780 million generated in the U.S. and $533 million from international markets. The company’s cost of sales totaled $318 million, including $65 million in third-party royalties, while research and development (R&D) expenses amounted to $583 million and selling, general, and administrative (SG&A) expenses were $282 million. Shares of Moderna rose 6.6% to close at $241.46 on November 5, 2026, ahead of the earnings release, before surging to $262.39 in extended trading, reflecting investor optimism about the company’s strategic direction [1][2].
Pipeline Advancements and Strategic Initiatives
Moderna’s operational milestones in late 2026 have positioned the company for sustained growth. In October 2026, the company and Merck presented positive Phase 3 INTerpath-001 study results for intismeran autogene (mRNA-4157) combined with KEYTRUDA at the ESMO Congress 2026, demonstrating a 42% reduction in the risk of recurrence or death in melanoma patients (HR=0.58). This breakthrough followed U.S. FDA approvals for mFLUSIVA in August 2026 and Health Canada authorization in September 2026. Additionally, Moderna completed a $3 billion convertible senior notes offering in September 2026, raising approximately $2.6 billion in net proceeds to strengthen its balance sheet [1].
Analyst Sentiment and Future Outlook
Wall Street analysts had anticipated a challenging quarter for Moderna, with consensus estimates projecting a loss of $1.25 per share and revenue of $890.22 million. However, the company’s actual results defied these expectations, prompting a reevaluation of its growth prospects. Piper Sandler maintained an Overweight rating with a price target increase from $167 to $230, while Goldman Sachs maintained a Neutral rating but raised its price target from $120 to $137. TD Cowen also upgraded its price target from $40 to $90, highlighting the evolving positive sentiment toward Moderna’s diversified pipeline and commercial strategy [2][4].
Corporate Background and Leadership
Founded in 2010 as ModeRNA Therapeutics and headquartered in Cambridge, Massachusetts, Moderna is led by Chief Executive Officer Stéphane Bancel and founder Noubar Afeyan. The company’s commercial portfolio includes Spikevax (COVID-19 mRNA vaccine) and mRESVIA (RSV mRNA vaccine for older adults), with an investigational pipeline targeting seasonal influenza, cytomegalovirus, combination respiratory infections, and cancer-related applications. This strategic diversification underpins the company’s confidence in achieving its upgraded 2026 guidance [3][GPT].